Part of TopicBrowse Topic in full-screen mode
Purpose: Small Cell Carcinoma (SmCC) is a rare and aggressive subtype of oesophageal cancer. This retrospective review evaluated outcomes to guide future treatment decisions.
Amongst 23 patients with LD, MS was 15.1 months and 1 year survival was 60%. MS for those who received chemotherapy alone, radiotherapy alone, concurrent chemo-radiotherapy and sequential chemo-radiotherapy was 8.4 months, 5.8 months, not yet reached and 20.1 months respectively (p=non-significant).
Amongst 29 patients with ED, MS was 5.2 months and 1 year survival was 26%. MS for those who received no treatment, chemotherapy alone, radiotherapy alone and sequential chemo-radiotherapy was 1 month, 4.5 months, 3.6 months and 16.2 months respectively (p=0.001).